retatrutide triple agonist glp-1 gip glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide mechanism of action triple

There is no evening decision fatigue, no "I will do it after dinner" that turns into "I forgot." Researchers who track their protocols using tools like the GLP-1 plotter consistently report better adherence with morning scheduling

When lifestyle changes arent giving you the results you want, GLP-1 medications could be worth a try

For many people, nausea improves within a few weeks as the body adapts

You could be on semaglutide for years and, once you stop taking it, stop feeling the impact of the weight-loss medication on your hunger levels

GLP-1 medications are powerful prescription drugs that require medical supervision

When you feel genuinely satisfied after meals, there's less room for sugar to sneak into the picture